炎症性肠病患儿对英夫利昔单克隆抗体治疗失应答的影响因素研究进展

Recent advance in influencing factors of non-response to Infliximab therapy in children with inflammatory bowel disease

炎症性肠病(IBD)是包括克罗恩病、溃疡性结肠炎和未定型结肠炎在内的一组病因不明的慢性非特异性胃肠道炎症性疾病。近年来儿童IBD的发病率逐年增加,对患儿、家庭及社会造成了相当大的疾病负担。英夫利昔单克隆抗体(IFX)作为一种有效的重要治疗方法,近年来临床上对其出现失应答的IBD患儿逐渐增多,其原因复杂且不明确。本文将对可能导致IBD患儿对IFX治疗出现失应答的因素进行讨论和归纳,以期寻找合适的方法提高IFX对IBD患儿的治疗效果。

Inflammatory bowel disease(IBD)is a group chronic inflammatory gastrointestinal diseases with unknown etiology,which includes Crohn′s disease,ulcerative colitis and indeterminate colitis.The number of pediatric IBD patients increases year by year and the disease causes a huge burden on patients,families and society.Infliximab(IFX)is an effective and important drug,but more and more patients don′t respense to it.The reason for non-respense is complex and unclear.This review discussed the factors that may cause failure to respond to IFX,in order to find a suitable method to improve the therapeutic effect of IFX on children with IBD.